$OPT:ASX - OPTHEA - Broken through resistance

Looks to have finally broken through a previous strong area of resistance with the announcement of moving their trial results forward. I like the biopharmaceutical space and anything to do with eye disease and diabetes would seem to be a good medium to long term opportunity. Might be worth a watch.

Opthea Limited (ASX:OPT), is a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases and is pleased to announce that the timing of the primary analysis from its ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) will occur sooner than expected and be brought forward by one quarter, with the primary data now expected to be reported in the 3rd quarter of calendar year 2019.

코멘트:

Nice little next day 8-10% gain.

거래청산: 스탑 닿음:

Stopped out on the dip. Will keep an eye on it. I like the stock.

코멘트:

Well it broke out alright. Sadly I wasn't still on it...

코멘트:

Looking for another entry.

코멘트:

Might be at a good place to look for a re-entry.